It’s Not Just for Sci-Fi: Using Artificial Intelligence to Identify Kidney Disease
It’s Not Just for Sci-Fi: Using Artificial Intelligence to Identify Kidney Disease
Successful development and implementation of an artificial intelligence-driven clinical decision support system for detection and treatment of acute kidney injury in the emergency department may improve the quality of kidney care and generate best practice methods to advance the application of artificial intelligence as well as develop a scalable CDS product.
Kidney disease is common but difficult to detect
Providers delivering care in the emergency department (ED) are faced with making high-stakes clinical decisions in a high-volume, time-sensitive, and hectic environment. Acute kidney injury (AKI) is a very common condition for patients presenting in the ED and is associated with adverse clinical outcomes. Unlike conditions such as heart attack, where a provider witnesses a patient wincing in pain, or stroke, where a provider can rapidly measure a patient’s strength and assess their speech, it is difficult to identify kidney injury quickly. Detection and assessment of the severity of AKI in the ED setting is limited due to laboratory-based diagnostic criteria and a general lack of syndrome recognition. Diagnosis of AKI currently relies on detection of changes in serum creatinine (sCr) concentration and urine output, both of which may take several days to manifest and identify.
Complex pattern matching
To address this diagnosing challenge, Drs. Jeremiah Hinson and Scott Levin and a Johns Hopkins University-based research team are betting that artificial intelligence (AI) techniques will be able to extract and analyze relevant electronic health record (EHR) data for AKI detection and treatment in emergency point-of-care clinical decision support (CDS). They are developing an EHR-based algorithm to estimate AKI risk and flag patients at high risk for AKI. This algorithm will then be translated into an AKI-CDS system and pilot-tested among emergency department providers. While it sounds very complicated, Dr. Hinson describes it as pattern matching that is very complex.
Innovative research that can be scaled and disseminated
Dr. Hinson and team believe this research is highly innovative and will have an impact, as it will generate important knowledge and tools to advance the study and application of AI in the ED; this will result in a CDS product that is scalable via distribution platforms such as AHRQ’s CDS Connect. This research has the capacity to improve the quality of kidney care delivered to more than 1 million patients affected by AKI in the United States every year.